CS
BPMC

Candriam SCA’s Blueprint Medicines BPMC Stock Holding History

Candriam SCA’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,066
Closed -$5.61M – 688
2024
Q2 		$5.61M Buy
52,066
+12,001
+30% +$1.2M 0.03% 327
2024
Q1 		$3.8M Sell
40,065
-10,156
-20% -$871K 0.02% 396
2023
Q4 		$4.63M Sell
50,221
-85,001
-63% -$5.51M 0.03% 340
2023
Q3 		$6.79M Sell
135,222
-16,000
-11% -$855K 0.05% 272
2023
Q2 		$9.56M Sell
151,222
-302,790
-67% -$16.5M 0.07% 253
2023
Q1 		$18.8M Buy
454,012
+195,701
+76% +$8.82M 0.13% 172
2022
Q4 		$11.3M Hold
258,311
– – 0.08% 249
2022
Q3 		$17M Buy
258,311
+1,139
+0.4% +$73.2K 0.12% 185
2022
Q2 		$13M Buy
257,172
+67,731
+36% +$3.97M 0.11% 190
2022
Q1 		$12.1M Sell
189,441
-162,802
-46% -$11.7M 0.08% 232
2021
Q4 		$37.7M Buy
352,243
+39,293
+13% +$4.11M 0.24% 107
2021
Q3 		$32.2M Hold
312,950
– – 0.22% 111
2021
Q2 		$27.5M Sell
312,950
-38,931
-11% -$3.57M 0.19% 126
2021
Q1 		$37.9M Sell
351,881
-1
-0% -$100 0.32% 78
2020
Q4 		$39.5M Sell
351,882
-182,133
-34% -$19.2M 0.31% 78
2020
Q3 		$49.5M Sell
534,015
-344,629
-39% -$26.5M 0.47% 41
2020
Q2 		$68.5M Buy
878,644
+767,413
+690% +$51.9M 0.72% 20
2020
Q1 		$8.71M Buy
111,231
+40
+0% +$2.57K 0.1% 239
2019
Q4 		$8.91M Buy
+111,191
New +$8.32M 0.1% 242
2018
Q4 		– Sell
-45,000
Closed -$3.51M – 816
2018
Q3 		$3.51M Buy
45,000
+1,000
+2% +$69.5K 0.05% 388
2018
Q2 		$2.79M Hold
44,000
– – 0.04% 411
2018
Q1 		$4.04M Hold
44,000
– – 0.07% 325
2017
Q4 		$3.32M Buy
+44,000
New +$3.1M 0.06% 350

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Candriam SCA's BPMC Position: Q3 2024 in Review

Candriam SCA sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 52,066 shares — an estimated $5.61M sold.

Candriam SCA first reported a position in BPMC in Q4 2017 and held it in 23 quarters. The position peaked at $68.5M in Q2 2020. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Candriam SCA reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Candriam SCA sold 52,066 Blueprint Medicines shares in Q3 2024, an estimated $5.61M.
  • Candriam SCA first reported a position in Blueprint Medicines in Q4 2017 and held it in 23 quarters.
  • Candriam SCA's Blueprint Medicines position peaked at $68.5M in Q2 2020.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.